BBA
DSGN icon

Baader Bank Aktiengesellschaft’s Design Therapeutics DSGN Stock Holding History

Baader Bank Aktiengesellschaft’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,792
Closed -$136K – 453
2026
Q1 		$136K Sell
12,792
-7,208
-36% -$72.9K 0.01% 387
2025
Q4 		$188K Buy
+20,000
New +$157K 0.01% 407

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Baader Bank Aktiengesellschaft's DSGN Position: Q2 2026 in Review

Baader Bank Aktiengesellschaft sold out of Design Therapeutics (DSGN) in Q2 2026, closing a stake of 12,792 shares — an estimated $136K sold.

Baader Bank Aktiengesellschaft first reported a position in DSGN in Q4 2025 and held it in 2 quarters. The position peaked at $188K in Q4 2025. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Baader Bank Aktiengesellschaft reported no remaining Design Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Baader Bank Aktiengesellschaft sold 12,792 Design Therapeutics shares in Q2 2026, an estimated $136K.
  • Baader Bank Aktiengesellschaft first reported a position in Design Therapeutics in Q4 2025 and held it in 2 quarters.
  • Baader Bank Aktiengesellschaft's Design Therapeutics position peaked at $188K in Q4 2025.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Baader Bank Aktiengesellschaft's 13F filing for Q2 2026, filed 23 Jul 2026.